R
Robin R. Frey
Researcher at AbbVie
Publications - 35
Citations - 1418
Robin R. Frey is an academic researcher from AbbVie. The author has contributed to research in topics: Histone deacetylase & Kinase. The author has an hindex of 16, co-authored 35 publications receiving 1228 citations. Previous affiliations of Robin R. Frey include Abbott Laboratories.
Papers
More filters
Journal ArticleDOI
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Loren M. Lasko,Clarissa G. Jakob,Rohinton Edalji,Wei Qiu,Debra Montgomery,Enrico L. Digiammarino,T. Matt Hansen,Roberto M. Risi,Robin R. Frey,Vlasios Manaves,Bailin Shaw,Mikkel Algire,Paul Hessler,Lloyd T. Lam,Tamar Uziel,Emily J. Faivre,Debra Ferguson,Fritz G. Buchanan,Ruth L. Martin,Maricel Torrent,Gary G. Chiang,Kannan R. Karukurichi,J. William Langston,Brian T. Weinert,Chunaram Choudhary,Peter de Vries,John H. Van Drie,David L. McElligott,Kesicki Edward A,Ronen Marmorstein,Chaohong Sun,Philip A. Cole,Saul H. Rosenberg,Michael R. Michaelides,Albert Lai,Kenneth D. Bromberg +35 more
TL;DR: The results demonstrate the feasibility of using small molecule inhibitors to selectively target the catalytic activity of histone acetyltransferases, which may provide effective treatments for transcriptional activator-driven malignancies and diseases.
Journal ArticleDOI
Trifluoromethyl ketones as inhibitors of histone deacetylase.
Robin R. Frey,Carol K. Wada,Robert B. Garland,Michael L. Curtin,Michael R. Michaelides,Junling Li,Lori J. Pease,Keith B. Glaser,Patrick A. Marcotte,Jennifer J. Bouska,Shannon S. Murphy,Steven K. Davidsen +11 more
TL;DR: Trifluoromethyl ketones were found to be inhibitors of histone deacetylases (HDACs) and optimization led to the identification of submicromolar inhibitors such as 20 that demonstrated antiproliferative effects against the HT1080 and MDA 435 cell lines.
Journal ArticleDOI
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Yujia Dai,Yan Guo,Robin R. Frey,Zhiqin Ji,Michael L. Curtin,Asma A Ahmed,Daniel H. Albert,Lee D. Arnold,Shannon S Arries,Teresa Barlozzari,Joy Bauch,Jennifer J. Bouska,Peter F. Bousquet,George A. Cunha,Keith B. Glaser,Jun Guo,Junling Li,Patrick A. Marcotte,Kennan C. Marsh,Maria D Moskey,Lori J. Pease,Kent D. Stewart,Vincent S. Stoll,Paul Tapang,Neil Wishart,Steven K. Davidsen,Michael R. Michaelides +26 more
TL;DR: A number of compounds have been identified as displaying excellent in vivo potency and possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model.
Journal ArticleDOI
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
Michael L. Curtin,Robert B. Garland,H. Robin Heyman,Robin R. Frey,Michael R. Michaelides,Junling Li,Lori J. Pease,Keith B. Glaser,Patrick A. Marcotte,Steven K. Davidsen +9 more
TL;DR: A series of succinimide hydroxamic acids was prepared and evaluated in vitro for HDAC inhibition and tumor cell antiproliferation, and several appropriately substituted non-macrocyclic succ inimides were equipotent.
Journal ArticleDOI
α-Keto amides as inhibitors of histone deacetylase
Carol K. Wada,Robin R. Frey,Zhiqin Ji,Michael L. Curtin,Robert B. Garland,James H. Holms,Junling Li,Lori J. Pease,Jun Guo,Keith B. Glaser,Patrick A. Marcotte,Paul L. Richardson,Shannon S. Murphy,Jennifer J. Bouska,Paul Tapang,Terrance J. Magoc,Daniel H. Albert,Steven K. Davidsen,Michael R. Michaelides +18 more
TL;DR: α-Keto ester and amides were found to be potent inhibitors of histone deacetylase and exhibited significant anti-tumor effects in an in vivo tumor model.